Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) revealed its 2024 financial performance, recording RMB257 million (USD35 million) in revenues, a 146% year-on-year (YOY) increase. This growth was driven by the commercialization of the Toumai Laparoscopic Surgical Robot and SkyWalker Orthopedic Surgical Robot both domestically and internationally. Despite the revenue surge, the company reported an annual loss of RMB647 million (USD89 million), marking a significant YOY decline.
Toumai Robot’s Market Expansion
In 2024, the Toumai robot achieved 39 new global orders with over 30 commercial installations. As of now, cumulative commercial orders worldwide exceed 60. In China, its market share continued to rise, capturing over 60% in provincial top Class 3A hospitals and national top 100 hospitals. Internationally, the product expanded into emerging markets in Asia, Africa, and Latin America within just one year and achieved breakthroughs in the high-end European market, securing over 20 commercial orders.
SkyWalker Robot’s Global Synergy
SkyWalker leveraged its synergy with parent company MicroPort Scientific Corp. (HKG: 0853), achieving significant YOY growth in installed capacity, with a total of over 40 global orders. These orders covered medical institutions across five continents, including China, the United States, Germany, Italy, Belgium, Greece, Australia, and Brazil. Leading in domestic orthopedic surgical robot globalization, SkyWalker has assisted in nearly 2000 total knee replacement surgeries to date.-Fineline Info & Tech
Leave a Reply